Revenue (Tables)

6 Months Ended

Jun. 30, 2020

Disaggregation of Revenue [Abstract]

Disaggregation of Revenue [Table Text Block]

The following tables disaggregate our revenue from contracts with customers by business and geographic region (in millions):

	Three Months Ended June 30,
	2020						2019
Businesses	U.S.		OUS		Total		U.S.		OUS		Total
Endoscopy	$	190	$	158	$	348	$	270	$	200	$	470
Urology and Pelvic Health	162		66		228		248		100		348
Cardiac Rhythm Management	208		143		351		288		210		498
Electrophysiology	22		30		51		39		46		84
Neuromodulation	100		23		122		160		44		204
Interventional Cardiology	189		306		495		318		388		706
Peripheral Interventions	189		151		340		155		165		320
Specialty Pharmaceuticals	60		8		68		n/a		n/a		n/a
Net Sales	$	1,118	$	885	$	2,003	$	1,478	$	1,153	$	2,631

	Six Months Ended June 30,
	2020						2019
Businesses	U.S.		OUS		Total		U.S.		OUS		Total
Endoscopy	$	445	$	345	$	790	$	523	$	387	$	910
Urology and Pelvic Health	400		161		560		479		195		674
Cardiac Rhythm Management	463		325		788		576		413		989
Electrophysiology	53		72		126		75		89		164
Neuromodulation	250		63		313		304		86		390
Interventional Cardiology	486		642		1,128		614		753		1,367
Peripheral Interventions	413		319		732		311		320		631
Specialty Pharmaceuticals	97		12		109		n/a		n/a		n/a
Net Sales	$	2,607	$	1,939	$	4,546	$	2,881	$	2,243	$	5,124

	Three Months Ended June 30,				Six Months Ended June 30,
Geographic Regions	2020		2019		2020		2019
U.S.	$	1,058	$	1,478	$	2,510	$	2,881
EMEA (Europe, Middle East and Africa)	416		571		968		1,132
APAC (Asia-Pacific)	410		481		819		918
LACA (Latin America and Canada)	51		101		140		192
Medical Devices	1,935		2,631		4,437		5,124
U.S.	60		n/a		97		n/a
OUS	8		n/a		12		n/a
Specialty Pharmaceuticals	68		n/a		109		n/a
Net Sales	$	2,003	$	2,631	$	4,546	$	5,124
Emerging Markets (1)	$	255	$	318	$	522	$	614

(1) We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets, which is currently comprised of the following countries: Argentina, Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Thailand, Turkey and Vietnam.